| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
HIV-1 protease; TNF-α production; NF-κB signaling. Ganoderic acid C1 suppresses TNF-α production in mouse macrophages and peripheral blood mononuclear cells. It inhibits LPS-induced NF-κB activation. The compound is moderately active against HIV-1 protease with an IC₅₀ of 180 µM. It also inhibits angiotensin-converting enzyme (ACE). Its anti-inflammatory activity is mediated through suppression of TNF-α production and NF-κB inhibition.
|
|---|---|
| ln Vitro |
Ganoderic acid C1 exhibits cytotoxicity in vitro against Lewis lung carcinoma (LLC), T-47D (breast cancer), Sarcoma 180, and Meth-A tumor cell lines. It suppresses TNF-α production in mouse macrophages (RAW 264.7 cells). At 20 µg/mL, it inhibits LPS-induced NF-κB activation in PBMCs from asthma patients. The compound has anti-tumor-promoting activity. It is moderately active as an HIV-1 protease inhibitor (IC₅₀ = 180 µM) and inhibits ACE.
|
| ln Vivo |
In vivo, ganoderic acid C1 has potential for treating TNF-α-mediated inflammation in asthma and other inflammatory diseases. It has anti-tumor-promoting activity. The compound’s ability to suppress TNF-α production suggests potential benefits in animal models of asthma and other inflammatory conditions. Further in vivo studies are needed to characterize its pharmacokinetic and pharmacodynamic properties, as well as its efficacy and safety profile.
|
| Enzyme Assay |
Non-cell-based assays for ganoderic acid C1 include HIV-1 protease inhibition assays using recombinant HIV-1 protease and a fluorogenic substrate. The enzyme is incubated with substrate in the presence of various concentrations of the compound, and protease activity is measured by fluorescence detection. The IC₅₀ of 180 µM is determined from the dose-response curve. ACE inhibition assays are performed using purified ACE and a fluorogenic substrate. NF-κB inhibition can be assessed using reporter gene assays.
|
| Cell Assay |
Cell-based assays for ganoderic acid C1 use RAW 264.7 mouse macrophage cells to assess TNF-α suppression. Cells are stimulated with LPS and treated with the compound at various concentrations, and TNF-α production in culture supernatant is measured by ELISA. For anti-tumor activity, cancer cell lines (LLC, T-47D, Sarcoma 180, Meth-A) are treated with the compound, and cell viability is assessed using MTT or similar assays. PBMCs from asthma patients are used to assess NF-κB inhibition.
|
| Animal Protocol |
In vivo studies of ganoderic acid C1 are limited. Based on its biological activities, potential animal models include: asthma models for evaluating anti-inflammatory effects; tumor xenograft models for evaluating anti-tumor activity; and models of HIV infection for evaluating protease inhibition. Standard protocols for these models involve administration of the compound followed by measurement of relevant endpoints.
|
| ADME/Pharmacokinetics |
Ganoderic acid C1 has a molecular formula of C₃₀H₄₄O₈ and a molecular weight of approximately 532.67 g/mol. It is a lanostane-type triterpenoid isolated from Ganoderma lucidum. The compound is soluble in DMSO. It should be stored under recommended conditions. It is intended for research use only.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for ganoderic acid C1 are limited. As a natural triterpenoid from Ganoderma lucidum, it is generally considered to have low toxicity. The compound exhibits cytotoxicity against cancer cell lines, indicating biological activity at certain concentrations. Standard laboratory safety practices should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Ganoderic acid C1 is a triterpenoid compound. It has been reported that Ganoderma lucidum contains ganoderic acid C1, and relevant data are available for reference.
Ganoderic acid C1 (GAC1) is a lanostane-type triterpenoid isolated from Ganoderma lucidum (Reishi). It exhibits cytotoxicity against various tumor cell lines including LLC, T-47D, Sarcoma 180, and Meth-A. The compound suppresses TNF-α production in mouse macrophages and PBMCs from asthma patients and inhibits LPS-induced NF-κB activation. It has anti-inflammatory activity for treating TNF-α-mediated inflammation in asthma, anti-tumor-promoting activity, and moderate HIV-1 protease inhibitory activity (IC₅₀ = 180 µM). It is for research use only. |
| Molecular Formula |
C30H42O7
|
|---|---|
| Molecular Weight |
514.65
|
| Exact Mass |
514.293
|
| Elemental Analysis |
C, 70.01; H, 8.23; O, 21.76
|
| CAS # |
95311-97-0
|
| PubChem CID |
471004
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.22g/cm3
|
| Boiling Point |
688.3ºC at 760mmHg
|
| Melting Point |
150-151 °C
|
| Flash Point |
384.1ºC
|
| Index of Refraction |
1.559
|
| LogP |
4.339
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
37
|
| Complexity |
1120
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
C[C@@]12C(=O)C[C@H]([C@H](C)CC(=O)C[C@@H](C)C(=O)O)[C@@]1(C)CC(=O)C1[C@]3(CCC(=O)C(C)(C)[C@@H]3C[C@@H](C2=1)O)C
|
| InChi Key |
YTVGSCZIHGRVAV-NJNFCIENSA-N
|
| InChi Code |
InChI=1S/C30H42O7/c1-15(10-17(31)11-16(2)26(36)37)18-12-23(35)30(7)25-19(32)13-21-27(3,4)22(34)8-9-28(21,5)24(25)20(33)14-29(18,30)6/h15-16,18-19,21,32H,8-14H2,1-7H3,(H,36,37)/t15-,16-,18-,19+,21+,28+,29-,30+/m1/s1
|
| Chemical Name |
(2R,6R)-6-[(5R,7S,10S,13R,14R,17R)-7-hydroxy-4,4,10,13,14-pentamethyl-3,11,15-trioxo-1,2,5,6,7,12,16,17-octahydrocyclopenta[a]phenanthren-17-yl]-2-methyl-4-oxoheptanoic acid
|
| Synonyms |
Ganoderic-Acid C1; Ganoderic Acid C1; Ganoderic-Acid-C1; Ganoderic Acid-C1
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 50 mg/mL (97.15 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (2.43 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (2.43 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.25 mg/mL (2.43 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9431 mL | 9.7153 mL | 19.4307 mL | |
| 5 mM | 0.3886 mL | 1.9431 mL | 3.8861 mL | |
| 10 mM | 0.1943 mL | 0.9715 mL | 1.9431 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
